All Posts
Protected: DES Pharma Consulting and Adept Packaging Announce Strategic Alliance to Integrate CMC Strategy with Pharmaceutical Packaging Execution
There is no excerpt because this is a protected post.
June 30, 2026
There is no excerpt because this is a protected post.
For biologics such as monoclonal antibodies, recombinant proteins, vaccines, and advanced cell and gene therapies,
A pre-IND meeting is one of the highest-leverage interactions a biologics sponsor will have with
When a pharmaceutical or life sciences company receives a Form 483, Warning Letter, or Consent
The Critical Bridge in Drug Development Technology transfer stands as one of the most pivotal—yet
Good Manufacturing Practice (GMP) is the lifeblood of the pharmaceutical industry. It is the minimum
In the modern drug development world, the transition from clinical phases to commercial viability is
The intersection of Artificial Intelligence and drug development reached a fever pitch on January 14,
The FDA’s January 2026 announcement on “Flexible Requirements for Cell and Gene Therapies” has sent
Developing a therapeutic from lab to commercial launch requires much more than scientific innovation. it
Start building reliable, high-quality drug development programs today.